
12 March 2020

ASCO Post Article / Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer

The ASCO Post covered ilixadencel and the MERECA study in an article titled, “Off-the-Shelf Dendritic Vaccine Shows Benefit in Kidney Cancer.”

Click here to read the full article: <http://bit.ly/3cUu8Y8>

FOR MORE INFORMATION, PLEASE CONTACT:

Alex Karlsson-Parra, Interim CEO, Immunicum
Telephone: +46 8 732 8400
E-mail: info@immunicum.com

Michaela Gertz, CFO, Immunicum
Telephone: +46 70 926 17 75
E-mail: ir@immunicum.com

ABOUT IMMUNICUM AB (PUBL)

About Immunicum AB (publ) Immunicum is establishing a unique immuno-oncology approach through the development of allogeneic, off-the-shelf cell-based therapies. Our goal is to improve survival outcomes and quality of life by priming the patient’s own immune system to fight cancer. The company’s lead product ilixadencel, consisting of pro-inflammatory allogeneic dendritic cells, has the potential to become a backbone component of modern cancer combination treatments in a variety of solid tumor indications. Immunicum has evaluated ilixadencel in several clinical trials including the recently completed exploratory Phase II MERECA study in kidney cancer and the Company is moving towards late-stage clinical development. Founded and based in Sweden, Immunicum is publicly traded on the Nasdaq Stockholm. www.immunicum.com